| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 09/26/2002 | US20020137891 Inserting a nucleic acid sequence encoding a heterologous polypeptide into a nucleic acid sequence encoding subunit of an oligomerisable protein scaffold, incorporating it into expression vector to express nucleic acid to produce monomer |
| 09/26/2002 | US20020137889 Stress resistant retroviruses |
| 09/26/2002 | US20020137888 Target module is prepared by binding selectively a target protein, modified to allow its detection, to a surrogate ligand that is linked to an individually detectable bead |
| 09/26/2002 | US20020137886 Insertion of cleavage sites in non-critical regions of the toxins which are susceptible to protease activity in non-target tissues and single chain forms activated by proteases in the target; botulism and tetanus toxins; confine activity to target site; side effect reduction |
| 09/26/2002 | US20020137720 Polynucleotide sequence; drug |
| 09/26/2002 | US20020137718 Nucleozymes |
| 09/26/2002 | US20020137717 Use of chimeric mutational vectors to change endogenous nucleotide sequences in solid tissues |
| 09/26/2002 | US20020137716 Administering nucleotide sequence |
| 09/26/2002 | US20020137715 Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis |
| 09/26/2002 | US20020137714 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 09/26/2002 | US20020137713 Modulation of cell matrices |
| 09/26/2002 | US20020137712 69109, a novel human tyrosine phosphatase and uses therefor |
| 09/26/2002 | US20020137711 Suppression of hematopoietic enzyme; organ grafting |
| 09/26/2002 | US20020137710 Insect control agent |
| 09/26/2002 | US20020137709 Gene silencing using mRNA-cDNA hybrids |
| 09/26/2002 | US20020137708 Antitumor agents |
| 09/26/2002 | US20020137707 Insertion of polynucleotide into blood vessel |
| 09/26/2002 | US20020137701 Administering exogenous genes |
| 09/26/2002 | US20020137700 Nucleic acids; genetic engineering |
| 09/26/2002 | US20020137699 Expression systems comprising chimeric promoters with binding sites for recombinant transcription factors |
| 09/26/2002 | US20020137698 Antisense inhibition of rad51 |
| 09/26/2002 | US20020137697 Chimeric receptor genes and cells transformed therewith |
| 09/26/2002 | US20020137695 A nucleotide, e.g., 6-(beta-D-2-Deoxyribofuranosyl)-5-hydro-methyl-8H-pyrimido(4,5 -c)(1,2)pyridazin-7-one-5'-triphosphate, incorporated into a polynuceotide or an oligomucleotide; viricides; labels |
| 09/26/2002 | US20020137679 Thrombospondins-1 and -2 are adhesive glycoproteins proteins that are angiogenesis inhibitors; portions of TSP- 1, TSP-2, endostatin, angiostatin, platelet factor 4, or prolactin linked to a portion of cartilage oligoeric matrix protein |
| 09/26/2002 | US20020137678 Treatment of ocular neovascularization and related diseases |
| 09/26/2002 | US20020137677 Soluble zalpha11 cytokine receptors |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137675 Polypeptides, termed PROTX polypeptides, as well as polynucleotides encoding PROTX and antibodies that immuno-specifically bind to a PROTX, variant, mutant, or fragment of a PROTX; detection/treatment of pathological states; kits |
| 09/26/2002 | US20020137671 Production and use of modified cystatins |
| 09/26/2002 | US20020137670 Transferrin polycation/DNA complexes for the systemic treatment of tumor diseases with cytotoxic proteins |
| 09/26/2002 | US20020137663 The anti-neoplastic agent ET-743 inhibits trans activation by SXR |
| 09/26/2002 | US20020137661 Incubating parental polynucleotide variants under conditions to generate annealed polynucleotides of heteroduplexes, which are then exposed to a cellular DNA repair system to convert to parental variants or recombined variants |
| 09/26/2002 | US20020137226 Marking the biopolymers to be fractionated with magnetic beads of different sizes or materials causes different migration speeds and thus causes different postions of the biolpolymers after migration |
| 09/26/2002 | US20020137215 Cells transformed with vectors carrying bacterial luciferase transposon cassettes for conferring bioluminescence properties |
| 09/26/2002 | US20020137214 Target plants are transformed using a plastid vector which contains heterologous DNA sequences coding for a phytotoxin detoxifying enzyme or protein |
| 09/26/2002 | US20020137213 Adenovirus particles with mutagenized fiber proteins |
| 09/26/2002 | US20020137212 Recombinant adenovirus expression vector as antitumor agents |
| 09/26/2002 | US20020137211 Method for establishing an expression system of spider dragline silk gene in bombyx mori |
| 09/26/2002 | US20020137210 Method for modifying genetic characteristics of an organism |
| 09/26/2002 | US20020137209 Nongenotropic effect occurs due to a ligand-induced activation of the ligand binding domain and genotropic effect occurs due to a ligand-induced activation of the DNA-binding domain of a steroid receptor |
| 09/26/2002 | US20020137206 Subculturing a cultured undifferentiated cell in a medium containing thidiazuron |
| 09/26/2002 | US20020137205 Lipid uptake assays |
| 09/26/2002 | US20020137204 Conditioned medium collected from a culture of feeder cells with laminin or collagen |
| 09/26/2002 | US20020137203 Identifying, testing, and treatments for diabetes and diabetic conditions and weight gain |
| 09/26/2002 | US20020137202 Diagnosis, treatment, and prevention of disorders associated with a FCTRX nucleic acid, polypeptide, or an antibody specific for it |
| 09/26/2002 | US20020137195 Contacting unoxidized carbon, silicon, or germanium substrate with a bromine- or iodine- containing reactant to form an unoxidized, bromine- or iodine-terminated carbon, silicon, or germanium substrate, reacting with alkene |
| 09/26/2002 | US20020137191 May be used for the insertion of exogenous DNA sequences into the bacteria of the invention |
| 09/26/2002 | US20020137190 High growth methanotrophic bacterial strain |
| 09/26/2002 | US20020137188 Method of modulating cell survival and reagents useful for same |
| 09/26/2002 | US20020137186 Lymphotropic agents and vectors |
| 09/26/2002 | US20020137184 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof |
| 09/26/2002 | US20020137183 Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 09/26/2002 | US20020137182 For obtaining and using a polypeptide other than oncogene BCL-2 that affects programmed vertebrate cell death |
| 09/26/2002 | US20020137181 14087, a novel serine protease molecule and uses therefor |
| 09/26/2002 | US20020137177 One or more amino acid residues being replaced by cysteine residues where at least some of cysteine residues are modified by replacing thiol hydrogen in cysteine residue with thiol side chain to form modified enzyme |
| 09/26/2002 | US20020137172 33167, a novel human hydrolase and uses therefor |
| 09/26/2002 | US20020137171 Nucleic acid encoding a polypeptide having hydrolase activity |
| 09/26/2002 | US20020137170 Dual-specificity protein tyrosine phosphatases that dephosphorylate both phosphotyrosine and phosphothreonine/serine residues |
| 09/26/2002 | US20020137169 Which encode the nicotinate nucleotide pyrophosphorylase protein; methods of producing nicotinic acid or nicotinic acid derivatives |
| 09/26/2002 | US20020137168 Designated developmental tyrosine kinases; expressed in multipotential haematopoietic cells, in embryonic stem cells, in brain tissue and in testis, but are not expressed mature lineage-restricted haematopoetic cells |
| 09/26/2002 | US20020137166 ASIP-related proteins |
| 09/26/2002 | US20020137164 Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof |
| 09/26/2002 | US20020137161 Protein expression and structure solution using specific fusion vectors |
| 09/26/2002 | US20020137158 Novel human polypeptide deformylase (PDF) |
| 09/26/2002 | US20020137152 Fermentation process for epothilones |
| 09/26/2002 | US20020137151 Process for the fermentative preparation of metabolic products and for the nucleotide sequences encoding for the sod gene |
| 09/26/2002 | US20020137150 Culture product containiong corynebacterium |
| 09/26/2002 | US20020137149 Process for the fermentative preparation of D-pantothenic acid and/or its salts |
| 09/26/2002 | US20020137148 Process for the enzymatic production of D-pantothenic acid and/or its salts |
| 09/26/2002 | US20020137146 Escherichia culture product |
| 09/26/2002 | US20020137145 Human erythropoietin gene: high level expression in stably transfected mammalian cells |
| 09/26/2002 | US20020137144 Culture product |
| 09/26/2002 | US20020137143 Antigrowth regulator; cell differentiation; anticarcinogenic agents |
| 09/26/2002 | US20020137142 Tango-73 nucleic acids |
| 09/26/2002 | US20020137140 Fermentation method for production of heterologous gene products in lactic acid bacteria |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137137 Genetic engineering; polypeptides |
| 09/26/2002 | US20020137135 Novel NPG-1 gene that is differentially expressed in prostate tumors |
| 09/26/2002 | US20020137134 Genetic engineering; glycoproteins |
| 09/26/2002 | US20020137133 Receptor proteins |
| 09/26/2002 | US20020137132 Genetic engineering; diagnosis of psychological disorders |
| 09/26/2002 | US20020137129 Polypeptides; genetic engineering; drug development |
| 09/26/2002 | US20020137127 Culture product; polypeptides |
| 09/26/2002 | US20020137119 Immunoassay; quantitative analysis |
| 09/26/2002 | US20020137115 Cgmp- visualizing probe and a method of detecting and quantifying of cgmp by using the same |
| 09/26/2002 | US20020137110 Detecting apoptosis |
| 09/26/2002 | US20020137101 Genetic engineered polypeptide |
| 09/26/2002 | US20020137095 Reelin protein CR-50 epitope region |
| 09/26/2002 | US20020137094 Method for improving thermostability of proteins, proteins having thermostability improved by the method and nucleic acids encoding the proteins |
| 09/26/2002 | US20020137089 Methods of determining the presence of double stranded nucleic acids in a sample |
| 09/26/2002 | US20020137087 Complexing; quantitative analysis |
| 09/26/2002 | US20020137086 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| 09/26/2002 | US20020137085 Multiplexed generation of chemical or physical events |
| 09/26/2002 | US20020137081 Genes differentially expressed in vascular tissue activation |
| 09/26/2002 | US20020137076 Reducing enzyme activity |
| 09/26/2002 | US20020137073 Nucleotide sequences coding for the MtrA and/or MtrB proteins |
| 09/26/2002 | US20020137069 Beta 2 adrenergic polymorphism detection |
| 09/26/2002 | US20020137065 Thymidine kinase |
| 09/26/2002 | US20020137063 Diagnosis, therapy of metabolism disorders; polymerase chain reaction |
| 09/26/2002 | US20020137062 Polymerase chain reactions |